Login to Your Account


LFT abnormalities ‘Incyte’ clinical hold for Geron; phase II snafu hits three

By Randy Osborne
Staff Writer

Thursday, March 13, 2014

While Geron Corp. awaits formal notification by letter from the FDA regarding the full clinical hold placed on imetelstat, shares crashed and investors had few answers to their questions about the surprising move.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription